Hyo-Soo Kim
Seoul National University Hospital
845 Papers
4.5K Citations
Hyo-Soo Kim is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Myocardial infarction & Medicine. The author has an hindex of 81, co-authored 767 publications. Previous affiliations of Hyo-Soo Kim include Samsung Medical Center & Seoul National University.
Chat about Author
Papers
Impact of Atrial Fibrillation on Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI): The K-TAVI Registry
Sang-Yoon Lee,Ki Hong Choi,Taek Kyu Park,Ji-Hoon Kim,Eun Kim,Sung-Ji Park,Seung Woo Park,Hyeon Cheol Gwon,Kiyuk Chang,Cheol Woong Yu,Ju-Han Kim,Youngjin Choi,In Ho Chae,Jae-Hwan Lee,Jun Hong Kim,Jong Seon Park,Won-Jang Kim,Young Won Yoon,Tae Hoon Ahn,Sang Rok Lee,Byoung-Joo Choi,Tae Hyun Yang,Cheol Ung Choi,Seung Ho Hur,Han Cheol Lee,Hun Sik Park,Hyo-Soo Kim,Seung-Hyuk Choi +27 more
TL;DR: In this paper , the impact of atrial fibrillation (AF) on Korean patients undergoing TAVI and demonstrate the status of antithrombotic therapy for these patients was identified.
3
Predictors of candesartan's effect on vascular reactivity in patients with coronary artery disease.
TL;DR: The candesartan's effect on vascular reactivity is more pronounced in patients with more severe endothelial dysfunction and arterial stiffness.
3
Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: Results from HOST-REDUCE-POLYTECH-ACS trial.
Kyu Sun Lee,Keun Ho Park,Kyung Woo Park,Seung-Woon Rha,Doyeon Hwang,Jeehoon Kang,Han Mo Yang,Hyun Jae Kang,Bon-Kwon Koo,Nam Ho Lee,Jay Young Rhew,Kook-Jin Chun,Young Hyo Lim,Jung Min Bong,Jang Whan Bae,Bong Ki Lee,Seok Yeon Kim,Won-Yong Shin,Hong-Seok Lim,Kyungil Park,Hyo-Soo Kim +20 more
TL;DR: In this paper , the authors evaluated the efficacy and safety of prasugrel-dose de-escalation therapy in patients with diabetes mellitus (DM)-acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI).
3
Late Late Stent Thrombosis after Intracoronary Brachytherapy: Learning from Brachytherapy Experiences in the Drug-Eluting Stent Era
Dong Ho Shin,Dong Ho Shin,Dong-A Kwon,Dong-A Kwon,Jin Wook Chung,Jin Wook Chung,Seung Pyo Lee,Seung Pyo Lee,Sung-A Chang,Sung-A Chang,Byung-Soo Kang,Kyung-Woo Park,Kyung-Woo Park,Hyun Jae Kang,Hyun Jae Kang,Bon-Kwon Koo,Bon-Kwon Koo,In-Ho Chae,In-Ho Chae,Hyo-Soo Kim,Hyo-Soo Kim,Dae-Won Sohn,Dae-Won Sohn,Byung Hee Oh,Byung Hee Oh,Myoung-Mook Lee,Young-Bae Park,Young-Bae Park,Yun-Shik Choi,Yun-Shik Choi +29 more
TL;DR: 2 cases of late stent thrombosis that occurred despite giving combined antiplatelet therapy are reported, and these maladies developed more than 4 years after intracoronary brachytherapy.
3
Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia.
Debra Kush,Hyo-Soo Kim,Da Yi Hu,Ji Liu,Waheeda Sirah,Aditi Sapre,Christine McCrary Sisk,John F. Paolini,Darbie Maccubbin +8 more
TL;DR: In a large-scale, multinational, 6-month study in dyslipidemic patients, ERN/LRPT 2g produced superior lipid-modifying efficacy vs placebo, whether administered alone or with concomitant statins.
3